These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1214 related items for PubMed ID: 17080735

  • 1. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 3. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 4. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G.
    Crit Rev Oncol Hematol; 2009 Apr 01; 70(1):83-91. PubMed ID: 18723369
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 01; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 7. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 01; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 8. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug 01; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

  • 9. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L, Denaro A, Agustoni F, Bajetta E.
    J Support Oncol; 2012 Aug 01; 10(2):65-71. PubMed ID: 22005217
    [Abstract] [Full Text] [Related]

  • 10. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan 01; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 11. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Jan 01; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 12. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
    Rigacci L, Landi C, Caruso JP, Puccini B, Alterini R, Carrai V, Perrone T, Bosi A.
    Leuk Res; 2012 Feb 01; 36(2):182-5. PubMed ID: 21752467
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 01; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar 01; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 15. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct 01; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 16. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

  • 17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr 01; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J, Gupta MC, Kaushal V, Bhutani G, Dhankar R, Atri R, Verma S.
    Singapore Med J; 2010 Nov 01; 51(11):871-5. PubMed ID: 21140114
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 01; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F.
    J Clin Oncol; 2005 Apr 20; 23(12):2822-30. PubMed ID: 15837996
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 61.